Investing.com -- Galenica Group’s (SIX:GALE) stock rose by more than 2% on Tuesday following its annual results for 2024, which posted strong growth across all core business segments.
The Swiss healthcare company reported a 4.7% increase in consolidated net sales, reaching CHF 3,921.1 million, reflecting its ability to outperform market growth and expand its market share in key areas.
The company’s adjusted EBIT increased by 10.3% to CHF 211.0 million, while adjusted net profit from continuing operations rose by 13.4% to CHF 183.2 million.
Given this robust performance, the Board of Directors will propose a dividend increase to CHF 2.30 per share, up 4.5% from the previous year.
Galenica’s Products & Care segment achieved net sales of CHF 1,700.2 million, growing 3.9% compared to the previous year.
Within this segment, the retail business generated CHF 1,442 million in revenue, with local pharmacies contributing CHF 1,365.1 million and pharmacies at home CHF 77.3 million.
The professionals business reported CHF 268.2 million in net sales, including products and brands sales of CHF 183.4 million and services for professionals revenue of CHF 84.8 million.
The logistics & IT segment recorded CHF 3,241.4 million in net sales. Within this segment, the wholesale business contributed CHF 3,105.2 million, while Logistics & IT services saw a 9.2% increase, reaching CHF 157.2 million.
In 2024, Galenica expanded its pharmacy network by 10 new locations, bringing the total to 376 pharmacies. The company strengthened its presence particularly in Bernese Oberland and Ticino, further enhancing access to healthcare across Switzerland.
Galenica pharmacies continued playing a key role in accessible healthcare, providing 193,000 customer consultations, a 39% increase over the previous year.
Demand for vaccinations rose by 20%, underscoring the growing importance of pharmacies in delivering healthcare services.
The wholesale sector saw strong momentum, particularly in the doctors’ segment, which grew by 7.8%, leading to additional market share gains.
Meanwhile, Verfora’s export business grew organically by 15.1%, driven by higher demand for Perskindolin Asia and earlier product deliveries ahead of regulatory changes.
Galenica continued to strengthen its home care services, including blister packaging, clinical nutrition, and home healthcare solutions.
Medifilm expanded its capacity by adding two new blister packaging machines, resulting in a 10% increase in patient numbers.
The business also gained 50 new institutional clients, further solidifying its leadership in medication packaging services.
In digital healthcare, Galenica rolled out the Prescription Manager in February 2025, enabling customers to digitally manage, view, and reorder repeat prescriptions.
The company will also expand its in-pharmacy consultation services, adding 25 more locations under the “Consultation plus” banner, including Sun Store pharmacies for the first time.
For the 2025 financial year, Galenica expects sales growth between 3% and 5% and anticipates an adjusted EBIT increase of 4% to 6%.